{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:10:19Z","timestamp":1791259819689,"version":"4.1.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100010198","name":"Ministerio de Asuntos Econ\u00f3micos y Transformaci\u00f3n Digital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR21\/00059"],"award-info":[{"award-number":["JR21\/00059"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["AEI PID2023-152265OB-I00"],"award-info":[{"award-number":["AEI PID2023-152265OB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bellvitge Biomedical Research Institute"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>ANCA-associated vasculitis (AAV) is a group of chronic diseases with relapses that associate organic damage because of the disease and its treatment. Avacopan is a new treatment indicated for AAV. We present the first experiences with avacopan in Spain as part of an Early Access program.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with AAV who started avacopan between June 2022 and September 2023 were included. For comparison, a historical cohort of patients diagnosed with AAV around the same time and treated without avacopan was also included.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-nine patients treated with avacopan were analysed. Twelve patients (41.4%) were male, and median age was 56\u2009years. Most patients were ANCA MPO positive (21\/29, 72.4%). The most frequently affected organ was the kidney (23\/29, 79.31%), with a mean estimated glomerular filtration rate (eGFR) of 23.2\u2009ml\/min. Mean follow-up was 456.8\u2009(\u00b1181.7)\u2009days with a remission rate of 86.2%. eGFR increased from 23.2\u2009(11.2) to 38.38\u2009(18.55)\u2009ml\/min after 12\u2009months of diagnosis. Two patients had adverse events related to avacopan (severe neutropenia and a gastrointestinal affectation), 13 infections were reported and one death. Patients treated with avacopan received a significantly lower cumulative dose of prednisone at 6 and 12\u2009months (P-values of 0.02 and &amp;lt;0.01, respectively) compared with historical controls. The evolution of GFR at 1\u2009year of follow-up and the incidence of relapse were similar in both groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The combination of avacopan with standard immunosuppressive therapy presents a good safety profile and provides added value by contributing to the control of AAV activity, increase GFR and removal of steroids.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae534","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T16:23:53Z","timestamp":1727799833000},"page":"2019-2026","source":"Crossref","is-referenced-by-count":27,"title":["The real-world use and effectiveness of avacopan in routine practice for the treatment of ANCA vasculitis. First experiences in Spain"],"prefix":"10.1093","volume":"64","author":[{"given":"Juliana","family":"Draibe","sequence":"first","affiliation":[{"name":"Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8299-0209","authenticated-orcid":false,"given":"Georgina","family":"Espigol-Frigol\u00e9","sequence":"additional","affiliation":[{"name":"Department of Autoimmune Diseases, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS) , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cinta","family":"Cid","sequence":"additional","affiliation":[{"name":"Department of Autoimmune Diseases, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS) , Barcelona,","place":["Spain"]},{"name":"Member of the European Reference Network, RITA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"Prados","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Torrec\u00e1rdenas Hospital , Almer\u00eda,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Guill\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Clinic , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Villacorta","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ram\u00f3n y Cajal Hospital , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Vega","sequence":"additional","affiliation":[{"name":"Department of Nephrology, La Paz Hospital , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Martins","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Getafe Hospital , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"daSilva","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Can Ruti , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00aa Adoraci\u00f3n","family":"Martin-Gomez","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Poniente , Almeria,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Huerta","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Puerta de Hierro Hospital , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Martinez-Valenzuela","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Morales","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de octubre(imas12) , Madrid,","place":["Spain"]},{"name":"Medicine Department, Complutense University of Madrid , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"2025040212120047500_keae534-B1","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2025040212120047500_keae534-B2","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"2","author":"Merkel","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2025040212120047500_keae534-B3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"2025040212120047500_keae534-B4","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ekir.2023.01.039","article-title":"Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of avacopan","volume":"8","author":"Cortazar","year":"2023","journal-title":"Kidney Int reports"},{"key":"2025040212120047500_keae534-B5","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2021.11.036","article-title":"Compassionate use of avacopan in difficult-to-treat antineutrophil cytoplasmic antibody-associated vasculitis","volume":"7","author":"van Leeuwen","year":"2021","journal-title":"Kidney Int reports"},{"key":"2025040212120047500_keae534-B6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025040212120047500_keae534-B7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.kint.2023.10.009","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the management of ANCA-associated vasculitis","volume":"105","author":"Floege","year":"2024","journal-title":"Kidney Int"},{"key":"2025040212120047500_keae534-B8","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2025040212120047500_keae534-B9","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.ekir.2024.07.007","article-title":"Avacopan in anti-neutrophil cytoplasmic autoantibodies-associated vasculitis in a real-world setting","volume":"9","author":"Zimmermann","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2025040212120047500_keae534-B10","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ekir.2024.03.022","article-title":"Real-world experience with avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"9","author":"Zonozi","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2025040212120047500_keae534-B11","article-title":"Avacopan for anti-neutrophil cytoplasm antibodies-associated vasculitis: a multicenter real-world study","author":"Gabilan","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025040212120047500_keae534-B12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/art.11115","article-title":"The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions","volume":"49","author":"Gonzalez-Gay","year":"2003","journal-title":"Arthritis Care Res"},{"key":"2025040212120047500_keae534-B13","first-page":"S-11-8","article-title":"Epidemiological study of primary systemic vasculitides among adults in southern Spain and review of the main epidemiological studies","volume":"33","author":"Romero-G\u00f3mez","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2025040212120047500_keae534-B14","doi-asserted-by":"crossref","first-page":"e6083","DOI":"10.1097\/MD.0000000000006083","article-title":"Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity","volume":"96","author":"Solans-Laqu\u00e9","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2025040212120047500_keae534-B15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s10067-017-3973-2","article-title":"Determinants of renal and patient outcomes in a Spanish cohort of patients with ANCA-associated vasculitis and renal involvement","volume":"37","author":"Marco","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025040212120047500_keae534-B16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.autrev.2011.04.024","article-title":"Refractory vasculitis","volume":"10","author":"Rutgers","year":"2011","journal-title":"Autoimmun Rev"},{"key":"2025040212120047500_keae534-B17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.berh.2018.07.009","article-title":"The complications of vasculitis and its treatment","volume":"32","author":"King","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae534\/60214406\/keae534.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/4\/2019\/60214406\/keae534.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/4\/2019\/60214406\/keae534.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T18:00:30Z","timestamp":1743616830000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/4\/2019\/7801474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":17,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,10,1]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae534","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,10,1]]}}}